

# 20 years clinical use of GP IIb/IIIa receptor antagonists: What have we learned and where to go?



EBAC ACCREDITED EDUCATIONAL PROGRAMME HELD DURING THE ESC CONGRESS 2014

## Introduction

# 20 years clinical use of GP IIb/IIIa receptor antagonists

**J. Wouter Jukema, MD, PhD**

Prof. of Cardiology  
Leiden University Medical Center,  
The Netherlands

Presented – September 1, 2014


# De-Thrombosis of Left Anterior Descending Coronary Artery With Abciximab

Initial Angiogram



Occluded 2nd diagonal branch and  
2nd septal perforating branch,  
and coronary thrombus

Angiogram Minutes After  
Abciximab Bolus



# EPIC data that we should still CAPTURE?

956

THE NEW ENGLAND JOURNAL OF MEDICINE

April 7, 1994

## USE OF A MONOCLONAL ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIb/IIIa RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY

THE EPIC INVESTIGATORS\*





Figure 1. Probability of No Urgent Repeated Percutaneous Revascularization Procedures in the Three Treatment Groups

**Conclusions.** Ischemic complications of coronary angioplasty and atherectomy were reduced with a monoclonal antibody directed against the platelet IIb/IIIa glycoprotein receptor, although the risk of bleeding was increased. (N Engl J Med 1994;330:956-61.)

The CAPTURE Investigators.

Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. *Lancet*. 1997;349:1429–1435.


# Background



Platelet-receptors with regard to different “anti-platelet” compounds

# The most critical point for PPCI is TIME

## GOLDEN PERIOD for myocardial salvage is first 2 hrs?



Is (early) timing of abciximab administration important?